{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:20:25Z","timestamp":1772810425554,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1998,3,1]],"date-time":"1998-03-01T00:00:00Z","timestamp":888710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1998,3,1]],"date-time":"1998-03-01T00:00:00Z","timestamp":888710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[1998,3]]},"DOI":"10.1006\/bcmd.1998.0166","type":"journal-article","created":{"date-parts":[[2002,10,6]],"date-time":"2002-10-06T20:07:46Z","timestamp":1033934866000},"page":"9-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Anagrelide for Treatment of Patients with Chronic Myelogenous Leukemia and a High Platelet Count"],"prefix":"10.1006","volume":"24","author":[{"given":"Oliver M","family":"Trapp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria K","family":"Beykirch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petro E","family":"Petrides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/bcmd.1998.0166_MD980166RF1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/10428199609074374","article-title":"Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival","volume":"22","author":"Hehlmann","year":"1996","journal-title":"Leuk Lymph"},{"key":"10.1006\/bcmd.1998.0166_MD980166RF2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/00003495-199447050-00007","article-title":"Anagrelide","volume":"47","author":"Spencer","year":"1994","journal-title":"Drugs"},{"key":"10.1006\/bcmd.1998.0166_MD980166RF3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-2007-996112","article-title":"Anagrelide as a new platelet lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications","volume":"23","author":"Tefferi","year":"1997","journal-title":"Sem Thromb Hemost"},{"key":"10.1006\/bcmd.1998.0166_MD980166RF4","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0609.1998.tb01064.x","article-title":"Anagrelide, a novel platelet lowering option in essential thrombocythemia: Treatment experience in 48 patients in Germany","author":"Petrides","year":"1998","journal-title":"Eur J Hematol"},{"key":"10.1006\/bcmd.1998.0166_MD980166RF5","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/0277-5379(83)90091-3","article-title":"Thrombohemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function","volume":"19","author":"Barbui","year":"1983","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1006\/bcmd.1998.0166_MD980166RF6","first-page":"A24","article-title":"Incidence of bleeding and thrombotic complications increase in advanced stages of chronic myeloid leukemia. A retrospective analysis of 182 patients","volume":"72","author":"Wehmeier","year":"1996","journal-title":"Ann Hematol"},{"key":"10.1006\/bcmd.1998.0166_MD980166RF7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1055\/s-2007-996114","article-title":"Relation of platelet abnormalities thrombosis and hemorrhage in chronic myeloproliferative disorders","volume":"23","author":"Wehmeier","year":"1997","journal-title":"Sem Thromb Hemost"},{"key":"10.1006\/bcmd.1998.0166_MD980166RF8","first-page":"1241","article-title":"Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features","volume":"10","author":"Cervantes","year":"1996","journal-title":"Leukemia"},{"key":"10.1006\/bcmd.1998.0166_MD980166RF9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.V44.4.483.483","article-title":"Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance","volume":"44","author":"Mason","year":"1974","journal-title":"Blood"},{"key":"10.1006\/bcmd.1998.0166_MD980166RF10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0002-9343(96)00061-7","article-title":"Chronic myelogenous leukemia: a review","volume":"100","author":"Cortes","year":"1996","journal-title":"Am J Med"},{"key":"10.1006\/bcmd.1998.0166_MD980166RF11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2141.1997.d01-1982.x","article-title":"Clinical features at diagnosis in 430 patients with chronic myeloid leukemia at a referral center over a 16 year period","author":"Savage","year":"1997","journal-title":"Brit J Hematol 96"},{"key":"10.1006\/bcmd.1998.0166_MD980166RF12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF00199157","article-title":"Interferon-alpha corrects thrombocytosis in patients with myeloproliferative disorders","volume":"25","author":"Ludwig","year":"1987","journal-title":"Cancer Immunol Immunother"},{"key":"10.1006\/bcmd.1998.0166_MD980166RF13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/0002-9343(78)90587-9","article-title":"Rapid reduction of platelets count in essential thrombocythemia by discontinuous flow platelet pheresis","volume":"64","author":"Younger","year":"1978","journal-title":"Am J Med"},{"key":"10.1006\/bcmd.1998.0166_MD980166RF14","first-page":"324","article-title":"Treatment of excessive thrombocythemia in chronic myeloid leukemia by thrombocytopheresis and intravenous Thio-TEPA","volume":"10","author":"Renner","year":"1987","journal-title":"Onkologie"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979698901668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979698901668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:17:39Z","timestamp":1761049059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979698901668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,3]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1998,3]]}},"alternative-id":["S1079979698901668"],"URL":"https:\/\/doi.org\/10.1006\/bcmd.1998.0166","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[1998,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anagrelide for Treatment of Patients with Chronic Myelogenous Leukemia and a High Platelet Count","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1006\/bcmd.1998.0166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1998 The Blood Cells Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}